You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

Screen for hepatitis B virus in all cancer patients starting systemic treatment. Find out more about hepatitis B virus screening and management.

Drug Formulary
About the Drug Formulary Email Drug Formulary Team

epcoritamab

Pronunciation: EP-koh-RIH-tah-mab
Other Name(s): Epkinly™
Appearance: colourless to slightly yellow solution

Drug Formulary information is intended for use by healthcare professionals. It is not intended to be medical advice. Some of the information, including information about funding for cancer drugs, does not apply to all patients. Cancer treatment plans are unique to each patient. If you are a patient, please speak with your healthcare team to understand how this information applies to you.

Drug Monograph

Nov 2024
Table of Contents
Eligibility Forms
pdf download Epcoritamab (Outpatient) - Relapsed or Refractory Diffuse Large B-Cell Lymphoma pdf download Epcoritamab (Inpatient) - Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Patient Info Sheet

Jan 2025

What it is used for

  • Epcoritamab is used to treat certain types of blood cancers called lymphomas (such as B-cell lymphomas and follicular lymphoma).
     
  • Epcoritamab is a T-cell engaging antibody. For more information on T-cell engaging antibodies, click here.


You might also be interested in

Funding & Reimbursement

Several payment sources exist for cancer drugs in Ontario, depending on the drug, disease indication, and how and where it is delivered.

View Funding & Reimbursement

Symptom Management

Many people living with cancer experience nausea, diarrhea and other symptoms from their treatment or disease.

View Symptom Management

Drug Safety and Administration

Find documents on drug safety and administration for healthcare providers, including calculations and recommendations.

View Drug Safety and Administration